>Amylin’s largest shareholder getting wind of the delay filed an SEC doc trying to push a sale (presumably to Lilly) yesterday.< Actually, the Eastbourne Capital story hit the wire on Monday: <a href="http://www.reuters.com/article/marketsNews/idINN0336168920081103" target="_blank">http://www.reuters.com/article/marketsNews/idINN0336168920081103</a> but I agree with your main point: the timing was suspicious.